

Regulated information

ASIT biotech appoints Dr. Mohamed Shamji, an internationally recognized expert on allergy immunotherapy, as Scientific Advisor for the discovery of new drug candidates and for pre-clinical activities

Brussels, Belgium, 26 July 2016 – ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces the appointment of Dr. Mohamed Shamji as Scientific Advisor for the development of new drug candidates.

Dr. Shamji will provide ASIT biotech's pre-clinical research teams with his support and expertise in immunology with the principal objective of characterizing the immunological properties of new drug candidates.

"I am honored to have this opportunity to advise ASIT biotech, which implements an innovative approach in the field of allergen immunotherapy. Based on fragments of highly-purified natural allergens of an optimal size, the peptides used by ASIT biotech elicit protective B cell responses by inducing antibodies capable of blocking allergic reactions. This property represents a major point of differentiation vis-à-vis current allergy immunotherapy strategies based on peptide use. I am eager to explore the potential of ASIT biotech's technological platform in the treatment of new allergies", says Dr. Shamji.

Dr. Shamji completed his clinical scientist fellowship training in clinical immunology at the Chelsea & Westminster Hospital NHS Foundation Trust in London, United Kingdom, in 2004. He then pursued his interest in translational research and completed PhD studies in allergy and clinical immunology at the National Heart & Lung Institute, Imperial College London in 2010. Dr. Shamji has recently established his research group (Immunomodulation and Tolerance group) within the Allergy and Clinical Immunology Section at Imperial College London led by Professor Stephen Durham. In recognition of his research and academic achievements, he was awarded the Imperial College President's Award for outstanding Early Career Researcher in 2015.

Dr. Shamji has over 40 peer-reviewed publications in high impact journals and his two recent publications in the Journal of Allergy and Clinical Immunology were selected as editor's choice. For his complete scientific biography, please click [here](#).

Thierry Legon, CEO of ASIT biotech, concludes: *"As we continue to structure our team, we are delighted to henceforth be able to collaborate more closely with Dr. Shamji, an acknowledged expert in the field of allergen immunotherapy. His expertise in immunological tolerance induction mechanisms represents a real asset for identifying new routes of development for ASIT biotech, which already has two innovative product candidates targeting grass pollen and house dust mites."*

About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline entails two

novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.

Contact

Company

Thierry Legon, CEO
ASIT biotech
Tel. +32 2 264 03 90
investors@asitbiotech.com

Media and Investor Relations - France

NewCap
Dusan Oresansky / Pierre Laurent
Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu

Media Relations - Belgium

Laure-Eve Monfort
Tel.: +32 2 290 90 93
monfort@comfi.be

Forward Looking Statements

All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Important Legal Notice

This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The Company is responsible for the information contained in this press release.